Market Research Logo

Global Markets for Vaccine Technologies

Global Markets for Vaccine Technologies

Report Highlights
The global market for vaccine technologies reached $33.3 billion in 2016 and should reach $45.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2021.

Report Includes
An overview of the global market for human and animal (veterinary) vaccines
Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
A review of vaccine technology and its challenges, innovations, opportunities and regulatory hurdles
Evaluations of market sizes and developments for vaccine classes (prophylactic and therapeutic), vaccine types (inactivated, conjugate, attenuated, recombinant vector, subunit, toxoid, combination and dendritic cells), vaccine end-users (humans and animals) and disease indications (infectious, cancer and allergy)
Examination of industry environment, strategies, market influences and driving forces
Identification of regional market sizes, prices and trends
Analysis of relevant patents
Profiles of major players in the industry

Report Scope
The scope of this study entails the current market for human and animal vaccines. The report also includes regulatory aspects, current and developing technologies, market projections and market share. An analysis of patents, clinical trials, innovations and opportunities, as well as the latest trends is also discussed.

Sales data for the global and regional markets were corroborated for the present and forecasted values based on statistical analysis. Regions are categorized into the United States, Europe and the emerging markets, which include India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand. The application of vaccines in various diseases is discussed from both a commercial and R&D perspective.


The scope of this study entails the current market for human and animal vaccines. The report also includes regulatory aspects, current and developing technologies, market projections and market share. An analysis of patents, clinical trials, innovations and opportunities, as well as the latest trends is also discussed.

Sales data for the global and regional markets were corroborated for the present and forecasted values based on statistical analysis. Regions are categorized into the United States, Europe and the emerging markets, which include India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand. The application of vaccines in various diseases is discussed from both a commercial and R&D perspective.

CHAPTER 1 INTRODUCTION
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ANALYSTS' CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR VACCINE TECHNOLOGIES, BY SEGMENT,
THROUGH 2021 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021
($ MILLIONS)
CHAPTER 3 OVERVIEW
DEFINITIONS
THE IMMUNE SYSTEM
HOW VACCINES WORK
TYPES OF IMMUNITY
ACTIVE
PASSIVE
ADVANTAGES OF VACCINATION
HISTORY OF VACCINES
TABLE 1 HISTORY OF VACCINES
TYPES OF VACCINES
ATTENUATED (LIVE) VACCINES
Types of Attenuated (Live) Vaccines
TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES
Advantages and Disadvantages of Attenuated (Live) Vaccines
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE)
VACCINES
INACTIVATED (KILLED) VACCINES
Types of Inactivated (Killed) Vaccines
TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES
Advantages and Disadvantages of Inactivated (Killed) Vaccines
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED
(KILLED) VACCINES
TOXOID VACCINES
Types of Toxoid Vaccines
TABLE 6 TYPES OF TOXOID VACCINES
Advantages and Disadvantages of Toxoid Vaccines
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES
SUBUNIT VACCINES
Types of Subunit Vaccines
TABLE 8 TYPES OF SUBUNIT VACCINES
Advantages and Disadvantages of Subunit Vaccines
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES
CONJUGATE VACCINES
Types of Conjugate Vaccines
TABLE 10 TYPES OF CONJUGATE VACCINES
Advantages and Disadvantages of Conjugate Vaccines
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE
VACCINES
RECOMBINANT VECTOR VACCINES
Types of Recombinant Vector Vaccines
TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES
Advantages and Disadvantages of Recombinant Vector Vaccines
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT
VECTOR VACCINES
DNA VACCINES
Types of DNA Vaccines
TABLE 14 TYPES OF DNA VACCINES
Advantages and Disadvantages of DNA vaccines
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
RNA VACCINES
TABLE 16 ADVANTAGES AND DISADVANTAGES OF RNA VACCINES
FIGURE 1 OVERVIEW OF HOW RNA-BASED VACCINES WORK
ADJUVANTS AND EXCIPIENTS
PATHOGEN COMPONENTS
PARTICULATE ADJUVANTS
TABLE 17 VACCINE EXCIPIENT AND MEDIA SUMMARY, EXCIPIENTS
INCLUDED IN U.S. VACCINES, BY VACCINE
INFECTIOUS DISEASES PREVENTABLE BY VACCINES
HUMAN DISEASES
Viral Diseases
TABLE 18 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES
Bacterial Diseases
TABLE 19 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES
ANIMAL DISEASES
Food-Producing Animals
TABLE 20 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES
FOUND IN FOOD-PRODUCING ANIMALS
TABLE 21 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES
FOUND IN FOOD-PRODUCING ANIMALS
TABLE 22 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN
FOOD-PRODUCING ANIMALS
Companion Animals
TABLE 23 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES
FOUND IN COMPANION ANIMALS
TABLE 24 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES
FOUND IN COMPANION ANIMALS
TABLE 25 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN
COMPANION ANIMALS
Other Animals
TABLE 26 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN
OTHER ANIMALS
TABLE 27 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION
AND OTHER ANIMALS
CHAPTER 4 REGULATORY ASPECTS
REGULATORY ASPECTS
WORLD HEALTH ORGANIZATION (WHO) PREQUALIFIED VACCINES
TABLE 28 WHO PREQUALIFIED VACCINES, JANUARY 2014-SEPTEMBER 2016
NEW PRODUCT APPROVALS
TABLE 29 NEWLY APPROVED VACCINES, 2014-SEPTEMBER 2016
RECALLS
TABLE 30 GLOBAL VACCINE RECALLS, JANUARY 2014-SEPTEMBER 2016
VACCINE SHORTAGE
TABLE 31 GLOBAL VACCINE SHORTAGE, JANUARY 2012-SEPTEMBER 2016
SIGNIFICANT REGULATORY DEVELOPMENTS IN VACCINE-PREVENTABLE
DISEASE PRODUCTS
CHAPTER 5 NEW DEVELOPMENTS
TABLE 32 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF SEPTEMBER
2016
ALLIANCES AND JOINT VENTURES
TABLE 33 ALLIANCES AND JOINT VENTURES FOR THE DEVELOPMENT OF
HUMAN AND ANIMAL VACCINES, JANUARY 2014-SEPTEMBER 2016
NEW PRODUCT LAUNCHES
TABLE 34 NEWLY VACCINES LAUNCHED, JANUARY 2014-SEPTEMBER 2016
CHAPTER 6 MARKET ANALYSIS OF HUMAN VACCINES
MARKET BY TYPE
MARKET OVERVIEW
MARKET REVENUE
TABLE 35 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH
2021 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021
($ MILLIONS)
MARKET SHARE
TABLE 36 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY
TYPE, 2015 (%)
FIGURE 3 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY
TYPE, 2015 (%)
MARKET BY REGION
MARKET OVERVIEW
MARKET REVENUE
TABLE 37 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH
2021 ($ MILLIONS)
FIGURE 4 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2014-2021 ($
MILLIONS)
MARKET SHARE
TABLE 38 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY
REGION, 2015 (%)
FIGURE 5 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY
REGION, 2015 (%)
REGIONAL MARKETS FOR ATTENUATED (LIVE) VACCINES
Market Overview
Market Revenue
TABLE 39 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE, BY
REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 6 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE BY
REGION, 2014-2021 ($ MILLIONS)
REGIONAL MARKETS FOR INACTIVATED VACCINES
Market Overview
Market Revenue
TABLE 40 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, BY
REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 7 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY
REGION, 2014-2021 ($ MILLIONS)
REGIONAL MARKETS FOR CONJUGATE VACCINES
Market Overview
Market Revenue
TABLE 41 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS)
FIGURE 8 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION,
2014-2021 ($ MILLIONS)
REGIONAL MARKETS FOR RDNA/ DNA VACCINES
Market Overview
Market Revenue
TABLE 42 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES
BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 9 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES
BY REGION, 2014-2021 ($ MILLIONS)
REGIONAL MARKETS FOR SUBUNIT VACCINES
Market Overview
Market Revenue
TABLE 43 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS)
FIGURE 10 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION,
2014-2021 ($ MILLIONS)
REGIONAL MARKETS FOR TOXOID VACCINES
Market Overview
Market Revenue
TABLE 44 GLOBAL MARKET FOR TOXOID VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS)
FIGURE 11 GLOBAL MARKET FOR TOXOID VACCINES BY REGION,
2014-2021 ($ MILLIONS)
REGIONAL MARKETS FOR OTHER/COMBINATION VACCINES
Market Overview
Market Revenue
TABLE 45 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY
REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 12 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY
REGION, 2014-2021 ($ MILLIONS)
CHAPTER 7 MARKET ANALYSIS OF ANIMAL VACCINES
MARKET OVERVIEW
MARKET REVENUE
TABLE 46 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET
LEADER, 2014-2016 ($ MILLIONS)
FIGURE 13 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET
LEADER, 2014-2016 ($ MILLIONS)
ANIMAL VACCINES
MARKET BY TYPE
TABLE 47 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH
2021 ($ MILLIONS)
FIGURE 14 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2014-2021
($ MILLIONS)
VACCINES USED IN FOOD-PRODUCING ANIMALS
Market Overview
Market Revenue
TABLE 48 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING
ANIMALS BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 15 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING
ANIMALS BY REGION, 2014-2021 ($ MILLIONS)
COMPANION ANIMAL VACCINES
Market Overview
Market Revenue
TABLE 49 GLOBAL MARKET FOR VACCINES FOR COMPANION
ANIMALS BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 16 GLOBAL MARKET FOR VACCINES FOR COMPANION
ANIMALS BY REGION, 2014-2021 ($ MILLIONS)
OTHER ANIMAL VACCINES
Market Overview
Market Revenue
TABLE 50 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY
REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 17 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY
REGION, 2014-2021 ($ MILLIONS)
MARKET SHARE
TABLE 51 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY
TYPE, 2015 (%)
FIGURE 18 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES
BY TYPE, 2015 (%)
MARKET BY REGION
MARKET OVERVIEW
MARKET REVENUE
TABLE 52 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH
2021 ($ MILLIONS)
FIGURE 19 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH
2021 ($ MILLIONS)
MARKET SHARE
TABLE 53 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY
REGION, 2015 (%)
FIGURE 20 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY
REGION, 2015 (%)
CHAPTER 8 INDUSTRY STRUCTURE
MARKET LEADERS IN HUMAN VACCINE
TABLE 54 LEADING MANUFACTURERS/ SUPPLIERS OF HUMAN VACCINES
MARKET SHARE OF HUMAN VACCINE
TABLE 55 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN
VACCINE, 2015 (%)
FIGURE 21 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN
VACCINE, 2015 (%)
MARKET LEADERS IN ANIMAL VACCINE
TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES
MARKET SHARE OF ANIMAL VACCINE
TABLE 57 ANIMAL VACCINE MANUFACTURERS' GLOBAL MARKET SHARE,
2015 (%)
FIGURE 22 ANIMAL VACCINE MANUFACTURERS GLOBAL MARKET SHARE,
2015 (%)
CHAPTER 9 MARKET BY APPLICATION FOR HUMAN VACCINES
PROPHYLACTIC VACCINES
THERAPEUTIC VACCINES
TABLE 58 HUMAN VACCINES BASED ON MICROORGANISM
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES
MENINGOCOCCAL
PNEUMOCOCCAL DISEASES
MARKET REVENUE
TABLE 59 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/
PNEUMOCOCCAL DISEASES, THROUGH 2021 ($ MILLIONS)
FIGURE 23 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/
PNEUMOCOCCAL DISEASES, 2014-2021 ($ MILLIONS)
MARKET SHARE
TABLE 60 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/
PNEUMOCOCCAL VACCINES, 2015 (%)
FIGURE 24 GLOBAL MARKET SHARES OF TOP-SELLING
MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015
(%)
INFLUENZA (SEASONAL AND PANDEMIC DISEASE)
MARKET REVENUE
TABLE 61 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES
MARKET, THROUGH 2021 ($ MILLIONS)
FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA
DISEASES MARKET, 2014-2021 ($ MILLIONS)
MARKET SHARE
TABLE 62 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA
VACCINES, 2015 (%)
FIGURE 26 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA
VACCINES, 2015 (%)
PEDIATRIC POLIO/PERTUSSIS/HIB
MARKET REVENUE
TABLE 63 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC
POLIO/PERTUSSIS/HIB DISEASES, THROUGH 2021 ($ MILLIONS)
FIGURE 27 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC
POLIO/PERTUSSIS/HIB DISEASES MARKET, 2014-2021 ($
MILLIONS)
MARKET SHARE
TABLE 64 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC
POLIO/PERTUSSIS/HIB VACCINES, 2015 (%)
FIGURE 28 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC
POLIO/PERTUSSIS/HIB VACCINES, 2015 (%)
ADULT/ADOLESCENT BOOSTER VACCINES
MARKET REVENUE
TABLE 65 GLOBAL MARKET FOR HUMAN VACCINES IN
ADULT/ADOLESCENT BOOSTER DISEASES, THROUGH
2021 ($ MILLIONS)
FIGURE 29 GLOBAL MARKET FOR HUMAN VACCINES IN
ADULT/ADOLESCENT BOOSTER DISEASES, 2014-2021 ($
MILLIONS)
MARKET SHARE
TABLE 66 GLOBAL MARKET SHARES OF TOP-SELLING
ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%)
FIGURE 30 GLOBAL MARKET SHARES OF TOP-SELLING
ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%)
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES
MARKET REVENUE
TABLE 67 GLOBAL MARKET FOR HUMAN VACCINES FOR
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES,
THROUGH 2021 ($ MILLIONS)
FIGURE 31 GLOBAL MARKET FOR HUMAN VACCINES FOR
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES,
2014-2021 ($ MILLIONS)
MARKET SHARE
TABLE 68 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%)
FIGURE 32 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%)
HPV DISEASE
MARKET REVENUE
TABLE 69 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, THROUGH
2021 ($ MILLIONS)
FIGURE 33 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, 2014-2021
($ MILLIONS)
MARKET SHARE
TABLE 70 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES,
2015 (%)
FIGURE 34 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES,
2015 (%)
ROTAVIRUS DISEASE
MARKET REVENUE
TABLE 71 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS,
THROUGH 2021 ($ MILLIONS)
FIGURE 35 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS,
2014-2021 ($ MILLIONS)
MARKET SHARE
TABLE 72 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS
VACCINES, 2015 (%)
FIGURE 36 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS
VACCINES, 2015 (%)
OTHER DISEASES
MARKET REVENUE
TABLE 73 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER
DISEASES SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 37 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER
DISEASES SEGMENT, 2014-2021 ($ MILLIONS)
MARKET SHARE
TABLE 74 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE
OTHER DISEASES SEGMENT, 2015 (%)
FIGURE 38 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE
OTHER DISEASES SEGMENT, 2015 (%)
MARKET SHARE OF APPLICATIONS
TABLE 75 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY
APPLICATION, 2015 (%)
FIGURE 39 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY
APPLICATION, 2015 (%)
CHAPTER 10 PATENT ANALYSIS
PATENTS BY YEAR
TABLE 76 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY
2014-SEPTEMBER 2016 (NUMBER OF PATENTS)
FIGURE 40 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY
2014-SEPTEMBER 2016 (NUMBER OF PATENTS)
PATENTS BY VACCINE TYPE
TABLE 77 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER
2016 (NUMBER OF PATENTS)
FIGURE 41 U.S. PATENTS BY TYPE OF VACCINES, JANUARY
2014-SEPTEMBER 2016 (NUMBER OF PATENTS)
PATENTS BY ASSIGNEE'S COUNTRY
TABLE 78 U.S. PATENTS BY ASSIGNEE'S COUNTRY, JANUARY
2014-SEPTEMBER 2016 (NUMBER OF PATENTS)
TABLE 79 GLOBAL PATENT SHARES BY PATENT HOLDER’S COUNTRY,
JANUARY 2014-SEPTEMBER 2016 (%)
FIGURE 42 PATENT SHARES BY PATENT HOLDER’S COUNTRY, JANUARY
2014-SEPTEMBER 2016 (%)
PATENTS BY COMPANY
TABLE 80 U.S. PATENTS BY COMPANY, JANUARY 2014-SEPTEMBER 2016
(NUMBER OF PATENTS)
PATENTS BY ASSIGNEE
TABLE 81 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER
2016 (NUMBER OF PATENTS)
FIGURE 43 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER
2016 (NUMBER OF PATENTS)
CHAPTER 11 CURRENT SITUATION
HUMAN VACCINES
DEVELOPMENT AND LAUNCH OF NEW VACCINES
INCREASED R&D EFFORTS
INCREASED DEMAND FROM EMERGING MARKETS
GOVERNMENT INITIATIVES FOR INCREASED IMMUNIZATIONS
HIGH PRICES OF VACCINES
PRICING PRESSURE
GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION (GAVI)
RISING CONCERNS OF ASSOCIATED RISK FACTORS
INADEQUATE VACCINE SUPPLY
COLLABORATIONS, LICENSING AGREEMENTS, MERGERS AND
ACQUISITIONS
ANIMAL VACCINES
CHAPTER 12 COMPANY PROFILES
ABBOTT LABORATORIES
AERAS GLOBAL
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BAXTER INTERNATIONAL INC.
BAYER ANIMAL HEALTH
BHARAT BIOTECH INTERNATIONAL LIMITED
BIOLOGICAL E. LTD.
BIO-MANGUINHOS
BIOPROPERTIES PTY LTD.
BOEHRINGER INGELHEIM GMBH
BUL BIO - NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD.
(BB-NCIPD LTD.)
CADILA HEALTHCARE LTD. (ZYDUS CADILA)
CEVA SANTE ANIMALE
CHINA NATIONAL BIOTEC GROUP (CNBG)
COLORADO SERUM COMPANY
CSL LIMITED
ELANCO ANIMAL HEALTH
EMERGENT BIOSOLUTIONS INC.
FATRO S.P.A.
GENVEC INC.
GENEONE LIFE SCIENCES INC
GEOVAX
GLAXOSMITHKLINE PLC
GREEN CROSS CORP
INSTITUT PASTEUR DE DAKAR
JAPAN BCG LABORATORY
LG LIFE SCIENCES
JOHNSON AND JOHNSON INC
MERCK & CO. INC.
MERIAL S.A.S.
NOVARTIS PHARMA AG
PANACEA BIOTEC LTD.
PFENEX INC.
PFIZER INC.
PROFECTUS BIOSCIENCES INC.
PT BIO FARMA
SANOFI PASTEUR
SERUM INSTITUTE OF INDIA LIMITED
STATENS SERUM INSTITUT
VALNEVA SE
VIRBAC
ZOETIS INC.
CHAPTER 13 APPENDIX I - ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report